Loading clinical trials...
Loading clinical trials...
A Dose Escalation Study to Assess the Efficacy and Tolerance of AF-219 in Subjects With Refractory Chronic Cough
Conditions
Interventions
Gefapixant
Placebo (for gefapixant)
Start Date
March 9, 2015
Primary Completion Date
February 1, 2016
Completion Date
February 9, 2016
Last Updated
October 22, 2020
NCT05599191
NCT05733533
NCT05628740
NCT03282591
Lead Sponsor
Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions